Loading page
Loading page
Loading substance route
Most common and preferred route. Material should be held under the tongue or against the cheek for 15-25 minutes before swallowing. Produces intense metallic taste and oral numbness. Heavy doses have been associated with fatalities.
Effects vary widely by individual, dose, and context.
The head space of 25I-NBOMe is described by many as remarkably light and underwhelming in comparison to the classical psychedelics. It is not uncommon for people to report feeling that their thought stream has maintained general normality in its specific style throughout low to moderate dosages. At high dosages however, mild to overwhelming cognitive alterations become present.
The visual geometry of 25I-NBOMe is often described as similar in appearance to that of LSD. They can be comprehensively described as algorithmic in geometric style, intricate in complexity, fine and zoomed out in detail, fast and smooth in motion, structured in shape, colourful in scheme, glossy in colour, sharp around the edges and mostly rounded across their corners. In comparison to other more commonly used psychedelics, they can be described as significantly more intricate than the visual geometry found within 2C-I and most of the 2C-x family and are completely on par with LSD, psilocin and DMT at appropriately high dosages. In terms of their behaviour, 25I-NBOMe's geometry leads onto Level 7A visual geometry with Level 7B remaining so far unconfirmed within this substance. They also seem to consistently build up in visual intensity when the tripper stares at a central point. This eventually envelops the visual field and creates the sensation that the tripper has broken through into a continuously shifting geometric landscape or structure with a vast sense of immersive physical size attributed to it.
25I-NBOMe is capable of producing a full range of hallucinatory states within the level 1-3 range extremely consistently. However, level 4 hallucinatory breakthroughs are reported but very uncommon and inconsistent in comparison to other more commonly used psychedelics such as psilocin, 2C-E and DMT.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
25I-NBOMe is not habit-forming and the desire to use it can actually decrease with use. The rapid development of tolerance makes compulsive use essentially impossible. It is most often self-regulating.
No physical dependence or withdrawal syndrome has been documented. As with other psychedelics, physical dependence does not develop with use.
The LD50 has not been determined. Deaths have occurred from doses as low as 2-3 blotters (approximately 1000-3000 µg depending on concentration). Anecdotal reports suggest dangerous effects begin appearing above 1000 µg, with potentially lethal effects for sensitive individuals at approximately 2000 µg, though some have survived much higher doses. The toxic dose appears highly variable between individuals and is not predominantly dose-dependent. Insufflation significantly increases overdose risk due to difficulty controlling dosage.
Acute cardiovascular effects including tachycardia, hypertension, and significant vasoconstriction occur during intoxication; severe overdoses can result in thrombosis and cardiac arrest, though serious cardiac events at common doses are uncommon.
Rhabdomyolysis (muscle tissue breakdown) occurs in severe overdoses and is one of the most frequently appearing symptoms in fatalities; this complication is associated with overdose-level doses rather than common recreational use.
Acute kidney injury has been documented in overdose cases, typically as a secondary complication of rhabdomyolysis rather than direct nephrotoxicity; this risk is primarily associated with severe overdoses.
Long-term neurological effects including memory and speech difficulties have been occasionally reported following use; animal studies suggest potential for reduced hippocampal neurogenesis, though human relevance is unclear.
Hyperthermia and temperature regulation suppression occur during intoxication; severe hyperpyrexia is documented in overdose cases and contributes to multi-organ complications.
Confusion, delirium, paranoia, and psychotic episodes have been documented, particularly at strong doses or higher. Anxiety and paranoia appear to occur more readily than with other psychedelics. At least one fatal stabbing occurred during a psychotic episode induced by the drug. Persistent anxiety and PTSD have been reported following difficult experiences. Delirious states can include aggression and agitation, presenting danger to users and those nearby.
Seizures are one of the most frequently appearing symptoms in severe overdoses and fatalities. This effect is far more common at doses exceeding heavy ranges and may manifest as status epilepticus lasting more than 5 minutes or requiring medical intervention to stop. Seizures were present in 3 of 7 patients in one analytically confirmed case series.
25I-NBOMe was first described in the scientific literature by Ralf Heim and colleagues at the Free University of Berlin around the year 2000, initially appearing in the form of conference abstracts. Heim provided a comprehensive account of the compound in his 2003 doctoral dissertation. The…
European Union ban implemented September 2014, requiring member states to establish control measures and criminal penalties by October 2, 2015
Possession, production, and sale is prohibited. Queensland explicitly scheduled 25I-NBOMe in April 2012, followed by New South Wales in October 2013. The federal government has no specific legislation concerning N-benzyl phenethylamines, with control occurring at state level.
The entire NBOMe series became controlled as of February 18, 2014, including 25I-NBOMe, 25C-NBOMe, 25B-NBOMe, and related compounds. Listed on Portaria SVS/MS nº 344.
Became a controlled substance in October 2015. Production, possession, and distribution are prohibited.
Initially controlled under the Medicines Act (395/87) as of March 15, 2013. Subsequently scheduled in the government decree on narcotic substances, preparations and plants as of 2022, making possession and use illegal.
Falls within the generic definition of phenethylamines in Schedule C of Government Decree 66/2012.
Added to Tabella I in February 2015. Classified as a Schedule 1 controlled substance with criminal penalties for possession, production, and distribution.
Classified as a Schedule I controlled substance. Possession, production, and distribution are prohibited.
Classified as a Schedule 2 controlled substance under New Zealand drug legislation.
Falls under the definition of a 'substitution drug' under the Act on Counteracting Drug Addiction and the Act on State Sanitary Inspection (2010). Marketing and production are penalized with administrative fines rather than criminal sanctions.
Russia was the first country to specifically regulate the NBOMe series. All NBOMe compounds, including 25I-NBOMe, became illegal in October 2011.
Included in a Decree amending the classification of illicit drugs, published in Official Gazette of RS No. 62/2013.
Specifically named as a controlled substance under Verzeichnis D of Swiss narcotics legislation.
Prohibited under Federal Law No. 14 of 1995, which criminalizes production, import, export, transport, buying, selling, possessing, and storing of narcotic and psychotropic substances. The UAE maintains a zero-tolerance policy for recreational drug use.
Permanently added to Schedule I effective October 27, 2016, after emergency scheduling on November 15, 2013. The DEA initially used emergency powers to temporarily schedule 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe. Several states including Florida (December 2012), Louisiana (May 2013), Virginia, and Georgia (April 2013) had enacted state-level scheduling prior to federal action.
Prohibited under the Suchtmittelgesetz (SMG) since June 26, 2019. Possession, production, and sale are criminal offenses.
Controlled under Schedule III of the Controlled Drugs and Substances Act as of October 31, 2016. Classified as a derivative of 2,5-dimethoxyphenethylamine, with the scheduling covering 2C-phenethylamines and their salts, derivatives, and isomers.
Regulated through the generic classification of phenethylamines in the Executive Order on Euphoriant Substances.
Listed in Anlage I of the Betäubungsmittelgesetz (Narcotics Act) as of December 13, 2014. Manufacturing, possessing, importing, exporting, buying, selling, procuring, or dispensing without a license is prohibited.
Banned in 2012-2013. The NBOMe series of psychoactives became controlled substances.
Designated as a narcotic drug effective November 1, 2015. Subject to strict criminal penalties under Japanese narcotics legislation.
Classified as a Lijst 1 substance under the Opiumwet (Opium Law). This is the most restrictive category for controlled substances in Dutch law.
Regulated through the generic scheduling of phenethylamines as of February 14, 2013.
Banned under broad psychoactive substance legislation enacted in 2011, which prohibits all psychoactive substances regardless of specific chemical classification.
Added to the list of prohibited substances in March 2015.
Added to the Narcotic Drugs Punishments Act under Swedish Schedule I (substances without medical use) effective August 1, 2013. Published by the Medical Products Agency in regulation LVFS 2013:15.
Placed in Class 4 of prohibited substances following the 2014 European Union decision.
Classified as a Class A drug under the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971, effective June 10, 2014. Class A carries the most severe penalties, including up to 7 years imprisonment for possession.
15 sources cited
